A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

Takeshi Suzuki, Yasutaka Sukawa, Chiyo K. Imamura, Toshiki Masuishi, Hironaga Satake, Yosuke Kumekawa, Shinsuke Funakoshi, Masahito Kotaka, Yoshiki Horie, Sadayuki Kawai, Hiroyuki Okuda, Tetsuji Terazawa, Chihiro Kondoh, Ken Kato, Kenichi Yoshimura, Hideki Ishikawa, Yasuo Hamamoto, Narikazu Boku, Hiromasa Takaishi, Takanori Kanai

Research output: Contribution to journalArticle

Abstract

To improve the tolerability and maintain sufficient efficacy of regorafenib, we conducted a phase II study of regorafenib with a lower starting dose of 120 mg/day for patients with refractory metastatic colorectal cancer. Using this dose-escalation strategy, the disease control rate for the 68 evaluable patients was lower than that in our statistical hypothesis, and a relationship of unbound exposure with toxicity was observed.

Original languageEnglish
JournalClinical Colorectal Cancer
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Colorectal Neoplasms
regorafenib

Keywords

  • Advanced colorectal cancer
  • Dose escalation
  • Multikinase inhibitor
  • Pharmacokinetics
  • Protein binding

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer : Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). / Suzuki, Takeshi; Sukawa, Yasutaka; Imamura, Chiyo K.; Masuishi, Toshiki; Satake, Hironaga; Kumekawa, Yosuke; Funakoshi, Shinsuke; Kotaka, Masahito; Horie, Yoshiki; Kawai, Sadayuki; Okuda, Hiroyuki; Terazawa, Tetsuji; Kondoh, Chihiro; Kato, Ken; Yoshimura, Kenichi; Ishikawa, Hideki; Hamamoto, Yasuo; Boku, Narikazu; Takaishi, Hiromasa; Kanai, Takanori.

In: Clinical Colorectal Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Suzuki, T, Sukawa, Y, Imamura, CK, Masuishi, T, Satake, H, Kumekawa, Y, Funakoshi, S, Kotaka, M, Horie, Y, Kawai, S, Okuda, H, Terazawa, T, Kondoh, C, Kato, K, Yoshimura, K, Ishikawa, H, Hamamoto, Y, Boku, N, Takaishi, H & Kanai, T 2019, 'A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)', Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2019.10.004
Suzuki, Takeshi ; Sukawa, Yasutaka ; Imamura, Chiyo K. ; Masuishi, Toshiki ; Satake, Hironaga ; Kumekawa, Yosuke ; Funakoshi, Shinsuke ; Kotaka, Masahito ; Horie, Yoshiki ; Kawai, Sadayuki ; Okuda, Hiroyuki ; Terazawa, Tetsuji ; Kondoh, Chihiro ; Kato, Ken ; Yoshimura, Kenichi ; Ishikawa, Hideki ; Hamamoto, Yasuo ; Boku, Narikazu ; Takaishi, Hiromasa ; Kanai, Takanori. / A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer : Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial). In: Clinical Colorectal Cancer. 2019.
@article{dede2e5d73ae4eabb3e63635c7523f4c,
title = "A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)",
abstract = "To improve the tolerability and maintain sufficient efficacy of regorafenib, we conducted a phase II study of regorafenib with a lower starting dose of 120 mg/day for patients with refractory metastatic colorectal cancer. Using this dose-escalation strategy, the disease control rate for the 68 evaluable patients was lower than that in our statistical hypothesis, and a relationship of unbound exposure with toxicity was observed.",
keywords = "Advanced colorectal cancer, Dose escalation, Multikinase inhibitor, Pharmacokinetics, Protein binding",
author = "Takeshi Suzuki and Yasutaka Sukawa and Imamura, {Chiyo K.} and Toshiki Masuishi and Hironaga Satake and Yosuke Kumekawa and Shinsuke Funakoshi and Masahito Kotaka and Yoshiki Horie and Sadayuki Kawai and Hiroyuki Okuda and Tetsuji Terazawa and Chihiro Kondoh and Ken Kato and Kenichi Yoshimura and Hideki Ishikawa and Yasuo Hamamoto and Narikazu Boku and Hiromasa Takaishi and Takanori Kanai",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.clcc.2019.10.004",
language = "English",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",

}

TY - JOUR

T1 - A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer

T2 - Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

AU - Suzuki, Takeshi

AU - Sukawa, Yasutaka

AU - Imamura, Chiyo K.

AU - Masuishi, Toshiki

AU - Satake, Hironaga

AU - Kumekawa, Yosuke

AU - Funakoshi, Shinsuke

AU - Kotaka, Masahito

AU - Horie, Yoshiki

AU - Kawai, Sadayuki

AU - Okuda, Hiroyuki

AU - Terazawa, Tetsuji

AU - Kondoh, Chihiro

AU - Kato, Ken

AU - Yoshimura, Kenichi

AU - Ishikawa, Hideki

AU - Hamamoto, Yasuo

AU - Boku, Narikazu

AU - Takaishi, Hiromasa

AU - Kanai, Takanori

PY - 2019/1/1

Y1 - 2019/1/1

N2 - To improve the tolerability and maintain sufficient efficacy of regorafenib, we conducted a phase II study of regorafenib with a lower starting dose of 120 mg/day for patients with refractory metastatic colorectal cancer. Using this dose-escalation strategy, the disease control rate for the 68 evaluable patients was lower than that in our statistical hypothesis, and a relationship of unbound exposure with toxicity was observed.

AB - To improve the tolerability and maintain sufficient efficacy of regorafenib, we conducted a phase II study of regorafenib with a lower starting dose of 120 mg/day for patients with refractory metastatic colorectal cancer. Using this dose-escalation strategy, the disease control rate for the 68 evaluable patients was lower than that in our statistical hypothesis, and a relationship of unbound exposure with toxicity was observed.

KW - Advanced colorectal cancer

KW - Dose escalation

KW - Multikinase inhibitor

KW - Pharmacokinetics

KW - Protein binding

UR - http://www.scopus.com/inward/record.url?scp=85075332951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075332951&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2019.10.004

DO - 10.1016/j.clcc.2019.10.004

M3 - Article

C2 - 31732439

AN - SCOPUS:85075332951

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

ER -